{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Daclatasvir&page=2", "query": { "intervention": "Daclatasvir", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Daclatasvir&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-27T13:22:11.273Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01389323", "title": "BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Daclatasvir", "type": "DRUG" }, { "name": "Peg-Interferon Alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 448, "start_date": "2011-09", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2015-10-12", "last_synced_at": "2026-09-27T13:22:11.273Z", "location_count": 35, "location_summary": "Montgomery, Alabama • Long Beach, California • Los Angeles, California + 24 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01389323" }, { "nct_id": "NCT00859053", "title": "Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatic Insufficiency" ], "interventions": [ { "name": "BMS-790052", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 46, "start_date": "2009-03", "completion_date": "2009-09", "has_results": true, "last_update_posted_date": "2015-10-08", "last_synced_at": "2026-09-27T13:22:11.273Z", "location_count": 2, "location_summary": "Anaheim, California • Orlando, Florida", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00859053" }, { "nct_id": "NCT02124044", "title": "Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-HCV" ], "interventions": [ { "name": "Asunaprevir and Daclatasvir", "type": "DRUG" }, { "name": "Asunaprevir and Daclatasvir with BMS-791325", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 30, "start_date": "2014-02", "completion_date": "2016-11", "has_results": true, "last_update_posted_date": "2017-05-16", "last_synced_at": "2026-09-27T13:22:11.273Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02124044" }, { "nct_id": "NCT01359644", "title": "Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "PSI-7977", "type": "DRUG" }, { "name": "Daclatasvir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 350, "start_date": "2011-06", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2015-10-23", "last_synced_at": "2026-09-27T13:22:11.273Z", "location_count": 17, "location_summary": "Coronado, California • San Diego, California • Aurora, Colorado + 13 more", "locations": [ { "city": "Coronado", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01359644" }, { "nct_id": "NCT01795911", "title": "Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Pegylated Interferon Lambda", "type": "BIOLOGICAL" }, { "name": "Ribasphere", "type": "DRUG" }, { "name": "Daclatasvir", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 165, "start_date": "2013-03", "completion_date": "2014-09", "has_results": false, "last_update_posted_date": "2015-10-09", "last_synced_at": "2026-09-27T13:22:11.273Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01795911" }, { "nct_id": "NCT02673489", "title": "A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "DCV", "type": "DRUG" }, { "name": "SOF", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2016-03-15", "completion_date": "2017-05-26", "has_results": true, "last_update_posted_date": "2018-05-08", "last_synced_at": "2026-09-27T13:22:11.273Z", "location_count": 12, "location_summary": "Los Angeles, California • San Francisco, California • Marietta, Georgia + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Catonsville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02673489" }, { "nct_id": "NCT01471574", "title": "Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C, Genotype 1" ], "interventions": [ { "name": "Daclatasvir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "PEG-Interferon alfa 2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 549, "start_date": "2011-12", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2016-01-29", "last_synced_at": "2026-09-27T13:22:11.273Z", "location_count": 23, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01471574" }, { "nct_id": "NCT01581203", "title": "Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "Asunaprevir (ASV)", "type": "DRUG" }, { "name": "Daclatasvir (DCV)", "type": "DRUG" }, { "name": "Pegylated-interferon alfa 2a (PegIFN)", "type": "DRUG" }, { "name": "Ribavirin (RBV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 748, "start_date": "2012-05", "completion_date": "2014-09", "has_results": false, "last_update_posted_date": "2015-10-09", "last_synced_at": "2026-09-27T13:22:11.273Z", "location_count": 18, "location_summary": "Montgomery, Alabama • La Jolla, California • Los Angeles, California + 14 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01581203" }, { "nct_id": "NCT02098616", "title": "Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "DCV/ASV/BMS-791325", "type": "DRUG" }, { "name": "DCV/ASV/BMS-791325 + RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Timothy Morgan, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2014-07", "completion_date": "2016-02", "has_results": false, "last_update_posted_date": "2016-04-19", "last_synced_at": "2026-09-27T13:22:11.273Z", "location_count": 1, "location_summary": "Long Beach, California", "locations": [ { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02098616" }, { "nct_id": "NCT01629732", "title": "Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "Daclatasvir", "type": "DRUG" }, { "name": "BMS-986094", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Placebo for BMS-986094", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2013-03", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2014-05-09", "last_synced_at": "2026-09-27T13:22:11.273Z", "location_count": 1, "location_summary": "Orlando, Florida", "locations": [ { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01629732" } ] }